PATENT CLAIM ANALYSIS

Application Number: 15933532
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "275000"]

Abstract:
This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.

Claim (Index 4):
The method of  claim 3 , wherein the cancer immunotherapy comprises a cell-based therapy, wherein the cell-based therapy comprises a cell selected from the group consisting of natural killer cell, a lymphokine-activated killer cell, a cytotoxic T cell, a regulatory T cell, and a dendritic T cell.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 90.0
- Lexical Diversity: 1.41176
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15109013', '15067605', '11292358', '15183486', '11332674']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7894534074206141
- 35 USC 102 Novelty (BERT): 0.5351289473252039
- Combined Prediction Score: 0.7640209614110731
- Mean Citation Score: 285.9536720000001
- Max Citation Score: 348.4242
- Similarity Product: 218.36360859797

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test